Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients

Background: Stereotactic ablative body radiotherapy (SABR) is one of the treatment options for oligometastatic renal cell carcinoma (RCC) but is limited by a lack of data to evaluate high-dose SABR to all/multiple sites. Objective: This study retrospectively investigated the efficacy and prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ming-Wei, Li, Hong-Zhen, Gao, Xian-Shu, Liu, Ming-Zhu, Yin, Huan, Yang, Kai-Wei, Chen, Jia-Yan, Ren, Xue-Ying, Wang, Dian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600736/
https://www.ncbi.nlm.nih.gov/pubmed/36290896
http://dx.doi.org/10.3390/curroncol29100619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600736/
https://www.ncbi.nlm.nih.gov/pubmed/36290896
http://dx.doi.org/10.3390/curroncol29100619

Ejemplares similares